Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie (Q81402838)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 February 2005

Language	Label	Description	Also known as
English	Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie	scientific article published on 12 February 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Jean-Yves Douillard

3

object named as

Jean-Yves Douillard

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Christine Lasset

8

object named as

Christine Lasset

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Sylvie Negrier

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Frédéric Gomez

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Christine Chevreau

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Murielle Buclon

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

David Perol

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Bernard Escudier

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Groupe Français d'Immunothérapie

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

12 February 2005

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

World Journal of Urology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

161-165

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15711829%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Fra

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15711829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q81402838&oldid=2221087658"